|
Drug Therapy
Contributing journals to this collection:
JAMA & Archives Journals
Citations 21-30 of 3664 total displayed.
- Original Investigations
Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data: Lessons for Postmarket Pharmaceutical Safety Surveillance
- Joseph S. Ross; David Madigan; Kevin P. Hill; David S. Egilman; Yongfei Wang; Harlan M. Krumholz
Arch Intern Med 2009; 169: 1976-1985.
[Abstract]
[Full text]
[PDF]
[ eFigure and eTables ]
- Invited Commentary
Bringing the FDA's Information to Market
- Steven Woloshin; Lisa M. Schwartz
Arch Intern Med 2009; 169: 1985-1987.
[Extract]
[Full text]
[PDF]
- Original Investigations
Physician and Pharmacist Collaboration to Improve Blood Pressure Control
- Barry L. Carter; Gail Ardery; Jeffrey D. Dawson; Paul A. James; George R. Bergus; William R. Doucette; Elizabeth A. Chrischilles; Carrie L. Franciscus; Yinghui Xu
Arch Intern Med 2009; 169: 1996-2002.
[Abstract]
[Full text]
[PDF]
- Original Investigations
Impact of a Pharmacist-Facilitated Hospital Discharge Program: A Quasi-Experimental Study
- Paul C. Walker; Steven J. Bernstein; Jasmine N. Tucker Jones; John Piersma; Hae-Won Kim; Randolph E. Regal; Latoya Kuhn; Scott A. Flanders
Arch Intern Med 2009; 169: 2003-2010.
[Abstract]
[Full text]
[PDF]
- Comments, Opinions, and Brief Case Reports
Direct-to-Consumer Offers for Free and Discounted Medications on the Internet: A Content Analysis of "e-Samples"
-
Arch Intern Med 2009; 169: 2024-2030.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
A Question of the Clinical Relevance of Determining Thrombomodulin Level While Receiving Anticoagulant Therapy—Reply
- Marcus Lind; Kurt Boman
Arch Intern Med 2009; 169: 2031-a-2032-a.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
A Question of the Clinical Relevance of Determining Thrombomodulin Level While Receiving Anticoagulant Therapy
- Chi Thi Nguyen; Gar Ming Chan; Mark Su
Arch Intern Med 2009; 169: 2031.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Optimal Anticoagulation Therapy in Patients With Valvular Heart Disease or Atrial Fibrillation
- Christopher J. McLeod; Bernard J. Gersh
Arch Intern Med 2009; 169: 2032-a-2033-a.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
The International Normalized Ratio Range of 2.0 to 3.0 Remains Appropriate for Atrial Fibrillation
- Daniel E. Singer; Margaret C. Fang; Alan S. Go
Arch Intern Med 2009; 169: 2032.
[Extract]
[Full text]
[PDF]
- Editor's Correspondence
Optimal Anticoagulation Therapy in Patients With Valvular Heart Disease or Atrial Fibrillation—Reply
- Marieke Torn; Frits R. Rosendaal
Arch Intern Med 2009; 169: 2033.
[Extract]
[Full text]
[PDF]
|
Advertisement


|
|
|